Octreotide as adjunctive therapy for catecholamine-secreting pheochromocytoma and paraganglioma
Authors' conclusion
Octreotide treatment was associated with biochemical, hemodynamic, and metabolic improvement
Study context
- Population
- Patients with catecholamine-secreting pheochromocytomas and paragangliomas (PPGLs) (14 paraganglioma, 13 pheochromocytoma) treated with octreotide at two referral centers in Muscat, Oman, January 2012–March 2026; 70.4% female; mean age 50.3 ± 22.2 years
- Participants
- 27 consecutive patients
- Exposure
- Octreotide treatment, before vs after
- Octreotiden = 27
- Outcome
- Clinical, hemodynamic and biochemical responses
Methodological detailsconsecutive patients, two referral centers
- Consecutive patients
- Two referral centers
Main finding
As reported in the abstract
- Median plasma norepinephrine decreased from 6,723 to 1,901 pmol/L
- P < 0.0001
- Mean blood pressure decreased from 154.8/93.5 to 123.0/75.3 mmHg (n = 16)
- P = 0.0003 for systolic and P = 0.0006 for diastolic pressure
Observational data: associations, not effects.
Secondary outcomes
HbA1c among patients with DM (n = 11)
- Mean HbA1c decreased from 8.6 ± 2.4% to 6.2 ± 0.8%
- P = 0.005
Surgical resection
- Underwent surgical resection
- 17 patients
Death during follow-up · median follow-up 3 years
- Non-PPGL-related death
- 1
Original publication
Octreotide as adjunctive therapy for catecholamine-secreting pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. Published 21 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →